Published in Pharma Law Weekly, June 28th, 2005
"Liver cancer is a leading cancer in Taiwan, especially in males. TACE is a major treatment for these patients, but research examining their fatigue experiences is limited," investigators in Taiwan reported.
"The purposes of this longitudinal, correlational study were to identify: (1) changes in fatigue, symptom distress, anxiety and depression in cancer patients across four time points during the first week of TACE treatment, and (2) factors predicting changes in fatigue across the four time...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.